儿科疾病药物研发商Mezzion获得2000万美元战略融资，推进Udenafil用于Fontan患者的全球3期临床开发-动脉网

Mezzion Secures $20 Million in Strategic Funding to Advance Global Phase 3 Clinical Development of Udenafil for Fontan Patients

CISION 等信源发布 2025-06-11 21:00



可切换为仅中文







SEOUL, South Korea

韩国首尔

，

June 11, 2025

2025年6月11日

/PRNewswire/ -- Mezzion Pharma Co., Ltd. (Mezzion) announced a major milestone in their clinical development program, having secured approximately

/PRNewswire/ -- Mezzion制药公司（Mezzion）宣布其临床开发项目取得了一个重要里程碑，已确保大约

$20 million USD

2000万美元

in strategic funding to support the ongoing global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation.

用于支持正在进行的udenafil全球三期FUEL-2试验，针对Fontan循环患者。

The financing was led by Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association, representing a strong vote of confidence from top-tier institutional investors in Mezzion's late-stage pipeline and long-term growth strategy.

本轮融资由 Midas-Meritz 新技术金融协会和 KDBC-韩国投资证券新技术投资协会领投，代表了顶级机构投资者对 Mezzion 公司后期研发管线及长期增长战略的强烈信心。

'We are pleased to partner with Midas Private Equity (Midas PE) and KDBC as we enter a critical phase in the development of udenafil for the Fontan population, a community with significant unmet medical need,' said

“我们很高兴与迈达斯私募股权（Midas PE）和KDBC合作，因为我们进入了为Fontan人群开发 udenafil 的关键阶段，这是一个具有重大未满足医疗需求的群体，”

Dean Park

迪恩公园

, Chairman and CEO of Mezzion. 'This investment affirms the strength of our data, the quality of our science, and the potential impact of our work on patients worldwide.'

梅zion公司董事长兼首席执行官表示：“这项投资肯定了我们数据的实力、科学的质量以及我们的工作对全球患者潜在的影响。”

Midas PE, the lead investor, is a prominent private equity firm with over

Midas PE，主导投资者，是一家拥有超过

$230 million

2.3亿美元

in assets under management. CEO

管理的资产。首席执行官

Lim Chun

林俊杰

-soo expressed strong confidence in Mezzion's direction:

-soo对Mezzion的发展方向表示了强烈的信心：

'After a detailed review of Mezzion's FUEL-1 results and the ongoing FUEL-2 protocol, we believe udenafil is well positioned for successful global Phase 3 completion and regulatory approval. We are proud to support Mezzion as it expands internationally and continues its leadership in rare disease innovation.'.

“在对Mezzion的FUEL-1结果和正在进行的FUEL-2方案进行详细审查后，我们相信udenafil有望顺利完成全球第三阶段试验并获得监管批准。我们很自豪能够支持Mezzion在国际上的扩展，并继续其在罕见病创新领域的领导地位。”

This financing follows growing clinical and regulatory momentum for Mezzion. The introduction of dedicated ICD-10 codes for Fontan-associated conditions marks a major step forward in recognizing and addressing the needs of this long-overlooked population. It enhances care, improves coverage, and underscores Mezzion's leadership and long-term commitment to advancing treatment for rare congenital heart disease..

这笔融资紧跟Mezzion在临床和监管方面的不断推进。针对Fontan相关病症引入专用的ICD-10编码，标志着在认识和满足这一长期被忽视人群需求方面迈出了重要一步。它提升了护理质量，改善了覆盖范围，并凸显了Mezzion在推进罕见先天性心脏病治疗方面的领导地位和长期承诺。

Chairman Park added, 'With accelerating enrollment and growing engagement across clinical sites, we believe time and data are now working in our favor. We have initially secured

朴主席补充道：“随着临床试验点的加速入组和参与度的提高，我们相信时间和数据现在对我们有利。我们已经初步确保了

$20 million

2000万美元

, and we will continue our efforts to receive valuable investments in the future.'

，我们将继续努力，以在未来获得有价值的投资。'

About Mezzion Pharma Co., Ltd.

关于Mezzion制药公司

Mezzion Pharma Co., Ltd., based in

总部位于韩国的Mezzion制药公司

South Korea

韩国

and listed on the KOSDAQ (140410), develops treatments for rare and underserved diseases. Its U.S. subsidiary, Mezzion Pharmaceuticals, Inc., headquartered in

在韩国科斯达克上市（代码：140410），致力于开发治疗罕见病和未满足需求疾病的药物。其美国子公司 Mezzion Pharmaceuticals, Inc. 总部位于

New Jersey

新泽西州

, leads global clinical development and commercialization. The company is currently advancing udenafil, a first-in-class therapy for patients with Fontan physiology, a rare congenital heart condition, now in global phase 3 trials.

，领导全球临床开发和商业化。该公司目前正在推进udenafil（一种用于治疗Fontan生理学患者的一流疗法），这是一种罕见的先天性心脏病，目前正处于全球第3阶段试验。

For more information, visit

欲了解更多信息，请访问

www.mezzion.com

mezzi昂.com

and

和

www.FUEL2Study.com

。

Media Contacts:

媒体联系人：

John Presser